comscoreResearch News

Research News

Find out what the latest clinical trial results mean for you.
More from this topic
1391 Research news
Fewer Breast Cancers Being Diagnosed During COVID-19 Pandemic

Far fewer cases of breast and five other cancers are being diagnosed during the COVID-19 pandemic.

Aug 18, 2020 | Screening and Testing
Breast Cancer Surgery Delays Don't Affect Survival in DCIS, Early-Stage Estrogen-Receptor-Positive Disease

Delaying breast cancer surgery for people diagnosed with DCIS or early-stage estrogen-receptor-positive invasive disease doesn't seem to affect survival.

Aug 19, 2020 | Diagnosis and Surgery
Starting Breast Cancer Screening at Age 40 Instead of 50 Saves Lives

Starting screening mammograms at age 40 instead of age 50 saves women's lives.

Aug 22, 2020 | Screening and Testing
Survey Suggests COVID-19 Pandemic Led to Delays in Care for Nearly Half of Breast Cancer Survivors

The early weeks of the COVID-19 pandemic caused 44% of breast cancer survivors to have a delay in care, according to an online survey.

Intraoperative Radiation Therapy During Lumpectomy Seems as Good as Traditional Whole-Breast Radiation Therapy for Early-Stage Breast Cancer

A single dose of radiation therapy given during lumpectomy surgery offered about the same outcomes for early-stage breast cancer as traditional whole-breast radiation therapy given after surgery.

ESMO Experts Release Recommendations on Managing Cancer Care During COVID-19 Pandemic

Recommendations from a European Society for Medical Oncology expert panel say doctors should not stop or delay any type of cancer treatment that might affect a person's overall survival and that all people diagnosed with cancer are not automatically at high risk for serious complications if they do get COVID-19.

Did Expanding Medicaid Reduce Differences in Breast Cancer Death Rates Between Black and White Women?

Expanded Medicaid coverage through the Affordable Care Act didn't seem to reduce the disparity in breast cancer death rates between Black and white women.

Aug 6, 2020 | Ethnicity
Trodelvy Improves Outcomes for Previously Treated Metastatic Triple-Negative Breast Cancer

Compared to standard chemotherapy, Trodelvy offered better outcomes for people diagnosed with previously treated metastatic triple-negative breast cancer.

Studies Show Conflicting Results With Tecentriq and Chemotherapy for Metastatic Triple-Negative Breast Cancer

When treating locally advanced or metastatic triple-negative breast cancer for the first time, adding Tecentriq to Taxol did not improve survival, while adding Tecentriq to Abraxane did improve survival.

Textured Implants May Be Linked to Breast Cancer Recurrence, Study Suggests

A small study found that women who had textured implants for reconstruction after breast cancer surgery had a small but statistically significant increase in the risk of the breast cancer coming back.

Oct 20, 2020 | Diagnosis, Surgery and Reconstruction
Piqray Improves Overall Survival for Advanced-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer With PIK3CA Mutation

Postmenopausal women and men diagnosed with advanced-stage hormone-receptor-positive, HER2-negative breast cancer with a PIK3CA mutation lived about 8 months longer when treated with the combination of the targeted therapy Piqray and the hormonal therapy Faslodex compared to Faslodex alone.

Adding Tecentriq to Chemotherapy Before Surgery for Early-Stage Triple-Negative Breast Cancer Improves pCR Rates

Adding Tecentriq to chemotherapy before surgery for early-stage triple-negative breast cancer offered higher pathologic complete response rates than chemotherapy alone, no matter the PD-L1 status of the cancer.

Radiation for Childhood, Young Adult Cancer Linked to Worse Survival After Premenopausal Breast Cancer

Women diagnosed with childhood or young adult cancer treated with radiation therapy who developed breast cancer before menopause were more likely to die from breast cancer compared to similar women who didn't have childhood or young adult cancer.

Sep 14, 2020 | Diagnosis and Risk Factors
Veliparib Maintenance After Chemo Slightly Improves Outcomes for Metastatic HER2-Negative Breast Cancer With BRCA Mutations

People diagnosed with metastatic HER2-negative breast cancer with a BRCA1 or BRCA2 mutation treated with experimental veliparib and chemotherapy lived about 2 months longer without the cancer growing if they continued on veliparib after stopping chemotherapy.

Early Results Suggest Ibrance Plus Faslodex as First Treatment Improves Outcomes for Metastatic Hormone-Receptor-Positive, HER2-Negative Breast Cancer

Adding Ibrance to Faslodex as a first treatment for advanced-stage or metastatic hormone-receptor-positive, HER2-negative breast cancer that either came back (recurred) more than 1 year after completing 5 or more years of hormonal therapy or was metastatic at first diagnosis improved progression-free survival compared to Faslodex alone.

Interval Breast Cancers Found Between Regular Screening Mammograms Seem More Aggressive

Breast cancers found in between regular screening mammograms (called interval cancers by doctors) were more likely to have aggressive characteristics, and women diagnosed with them were more likely to die from breast cancer compared to breast cancers found by routine screening.

Oct 27, 2020 | Screening and Testing
Boost Dose After Radiation for Moderate- or High-Grade DCIS Reduces Recurrence Risk

After whole-breast radiation, a boost dose to the area where the tumor was further reduced the risk of moderate- or high-grade DCIS coming back.

Aug 16, 2022 | Diagnosis and Radiation Therapy
Understanding How Mindfulness Meditation Reduces Pain

Mindfulness meditation seems to ease pain by allowing people to separate pain from things they’re experiencing.

A New Standard of Care? Enhertu Improves Survival in People With Metastatic HER2-Low Breast Cancer

Compared with doctors’ choice of chemotherapy, Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) improved both progression-free survival and overall survival in people diagnosed with previously treated metastatic HER2-low breast cancer.

FDA Approves Enhertu for Unresectable or Metastatic HER2-Low Breast Cancer

On Aug. 5, 2022, the U.S. Food and Drug Administration approved Enhertu to treat unresectable or metastatic HER2-low breast cancer.

Aug 5, 2022 | Targeted Therapy and Diagnosis
FDA Approves Immunotherapy Keytruda for PD-L1-Positive Triple-Negative Breast Cancer

On Nov. 13, 2020, the FDA approved the immunotherapy Keytruda in combination with chemotherapy to treat unresectable locally advanced or metastatic triple-negative, PD-L1-positive breast cancer.

Metformin Seems to Lower Risk of Estrogen-Receptor-Positive Breast Cancer in Women With Type 2 Diabetes

Women with type 2 diabetes who take metformin to control their blood sugar appear to have a lower risk of estrogen-receptor-positive breast cancer.

Feb 8, 2021 | Risk Factors
First Screening Mammography Guidelines for Older Breast Cancer Survivors Recommend Individualized Approach

The first screening mammography guidelines for breast cancer survivors age 75 and older encourage people and their doctors to come to a decision that is individualized for each person after discussing the benefits and risk of screening mammograms, as well as the person's preferences.

Feb 3, 2021 | Screening and Testing
Scalp Cooling Reduces Hair Loss by Lessening Chemotherapy Absorbed by Hair Follicles

A study offers a first peek at the biology behind scalp cooling by finding that scalp cooling dramatically reduces the amount of chemotherapy medicine absorbed by the hair follicles.

Feb 16, 2021 | Chemotherapy
Showing 24 of 1391